Image via Wikipedia Wikinvest--
Peregrine Pharmaceuticals PPHM
Google Finance--
Peregrine PPHM
Peregrine Pharmaceutical Pipeline
Press Release From November 9, 2004--Peregrine's commitment to treat Brain Cancer Patients:
Today's news seems positive. More Clinical Trials are necessary but this could be pushed through due to their orphan drug status.
Here is a news article designating Peregrine as receiving Orphan Drug Designation for Cotara in 2002. That is a long time but this is highly special needs cancer therapy that could be helpful if it gains FDA approval after Phase III clinical trials. It will possibly take another year or two but these will be pushed through accordingly. They use targeted Monoclonal Antibodies to kill the cancer tumors from the inside of the tumor without hurting surrounding cells. That is the theory. Hopefully it works and is approved for those at risk with Brain Tumors.
Peregrine Pharmaceuticals (Symbol: PPHM) Reports Promising Interim Survival Data From Phase II Cotara(R) Brain Cancer Study
October 18, 2010
Single Medical Center Reports Interim Median Overall Survival of 86 Weeks in Patients With
Glioblastoma Multiforme (GBM) Treated at First Relapse; Data Presented at 2010
Congress of Neurological Surgeons Annual Meeting
TUSTIN, CA and SAN FRANCISCO, CA,
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today reported interim data from an ongoing
Phase II clinical trial of its novel
brain cancer therapy Cotara(R). Interim median overall survival was 86 weeks for a cohort of 14 patients with glioblastoma multiforme (GBM) treated at first relapse with a single infusion of Cotara. Cotara is a targeted monoclonal antibody linked to a radioisotope that is administered directly into the tumor, destroying the tumor from the inside out, with minimal exposure to healthy tissue.
